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T helper 17 (Th17) cells play an important role in the pathogenesis of allergic asthma. Th17 cell differentiation requires Notch
signaling. 𝛾-Secretase inhibitor (GSI) blocks Notch signaling; thus, it may be considered as a potential treatment for allergic asthma.
The aim of this studywas to evaluate the effect of GSI onTh17 cell differentiation in amousemodel of allergic asthma. OVAwas used
to induce mouse asthma model in the presence and absence of GSI. GSI ameliorated the development of OVA-induced asthma,
including suppressing airway inflammation responses and reducing the severity of clinical signs. GSI also significantly suppressed
Th17-cell responses in spleen and reduced IL-17 levels in serum. These findings suggest that GSI directly regulates Th17 responses
through a Notch signaling-dependent pathway in mouse model of allergic asthma, supporting the notion that GSI is a potential
therapeutic agent for the treatment of allergic asthma.
1. Introduction
Asthma is an allergic disease characterized by airway inflam-
mation, mucin hypersecretion, and airway hyperresponsive-
ness (AHR) [1]. Infiltration of CD4+ T cells, eosinophils, mast
cells, and B cells and their interaction with airway resident
cells contribute to airway inflammation [2]. IL-17-producing
(Th17) CD4+Thcells are important players in asthma patho-
genesis [3, 4]. Numerous studies have shown an increase of
Th17 cells in inflammatory airway [5, 6].Therefore, suppress-
ing Th17 response may be a novel therapeutic strategy for
treating asthma. Notch signaling pathway is evolutionarily
conserved. In mammalian, there are four Notch receptors
(Notch1, Notch2, Notch3, andNotch4) and fiveNotch ligands
(Jagged1, Jagged2, Delta-like ligand (Dll)1, Dll3, and Dll4)
[7]. Notch plays a crucial role in a broad spectrum of
cellular activities such as proliferation, differentiation, and
regulation of cell function [8]. Notch signaling is initiated
when Notch receptors are engaged with a Notch ligand. A
series of enzymatic reactions lead to the cleavage of the Notch
receptor intracellular domain (NICD) which is translocated
to the nucleus, where it binds with CSL/RBP-Jk to recruit
Mastermind-like 1 protein. The newly formed complex then
initiates the transcription of downstream genes.
Previously, we showed that Notch signal pathway regu-
lates the proliferation and differentiation of CD4+ T lym-
phocytes in a mouse model of asthma, indicating that Notch
may be a potential target for treating asthma [9]. Others have
reported that pharmacologic inhibitor of Notch signaling can
reduce allergic pulmonary inflammation by modulating Th1
and Th2 responses [10, 11]. However, the exact protective
mechanism of Notch signaling in asthma remains unknown.
The present study aims to test whether GSI has therapeutic
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Figure 1: Flowchart of experimental design.
effects on the development of asthma through regulatingTh17
mediated immune response.
2. Materials and Methods
Experimental design is outlined in Figure 1.
2.1. Animal Model of Asthma. Male BALB/C mice, 4 to 6
weeks old, weighing 20–22 g, were purchased from Shanghai
Laboratory Animal Center (Shanghai, China) and bred in
pathogen-free environment in the animal center of Wen-
zhou Medical University. Animal experimental protocol was
approved by Institutional Animal Care and Use Committee
(IACUC) of Wenzhou Medical University. OVA induced
asthma was established as described previously [9]. Experi-
mental animals were divided into three groups: sham group,
OVA + DMSO (vehicle) group, and OVA + GSI (0.3mg/kg)
group. Mice were sensitized by i.p. injection of 10 𝜇g oval-
bumin (OVA) (Sigma, USA) emulsified in 20mg Al (OH)
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gel in 0.1mL normal saline (NS) on days 1 and 13. They
were then challengedwithOVA (1mg/mL) aerosol for 30min
daily for eight consecutive days from day 25 by Jet nebulizer
(Pari IS-2 Jet nebulizer; PARI Respiratory Equipment). GSI
L685,458 (Calbiochem, CA) was administered intranasally
30 minutes before each OVA challenge at 0.3mg/kg as
previously described [11]. The sham mice were sensitized
and challenged with normal saline (NS) and treatment with
dimethylsulfoxide (DMSO) as a control for GSI. Mice were
sacrificed within 24 h after the last allergen challenge.
2.2. Histopathological Examination. At the time of sacrifice,
the left lung tissue was first fixed with 4% paraformaldehyde
for 4 h. It was then dehydrated in ethylic alcohol, embedded
with paraffin, sectioned in 4 𝜇m, and stained with haema-
toxylin and eosin (HE). Tissue slices were evaluated through
light microscope (Nikon) by trained technician in a blind
fashion.
The degree of allergic airway inflammation was scored
according to the following histologic grading system (scored
0–4): absence of peribronchial inflammatory cells; a few
scattered peribronchial inflammatory cells involving less than
25%of the circumference of the bronchus; focal peribronchial
inflammatory cells infiltration not completely surround-
ing a bronchus (i.e., involving approximately 25%–75% of
the circumference of the bronchus); one definite layer of
peribronchial inflammatory cells completely surrounding a
bronchus; 2 or more layers of peribronchial inflammatory
cells completely surrounding a bronchus. In each lung section
the mean peribronchial inflammatory score was determined
by the sum of scores of all individual bronchioles in the
section divided by the number of bronchioles [12].
2.3. Preparation of Splenic Single-Cell Suspension. The spleen
tissue was fragmented into small pieces that were then
pressed against nylon mesh with a plunger of a disposable
syringe. Erythrocytes were lysed by red blood cell lysis buffer.
Cells were washed in PBS.
2.4. Isolation of CD4+ T Cells. CD4+ T cells from splenic
single-cell suspension were isolated by magnetic cell sorting
by positive selection method using mouse CD4+ T cell
isolation kit (MACS, Miltenyi Biotec, Germany) according
to the manufacturers’ instruction. The purity of the cells was
92.04 ± 5.18%, as confirmed by flow cytometry analysis.
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2.5. Flow Cytometry Analysis. FITC-labeled anti-mouse CD4
and PE-labeled anti-mouse IL-17A were used to detect Th17
cells.Matching IgGwas used as isotype control. All antibodies
were purchased from BD Bioscience, USA.
ForTh17 cell analysis, CD4+ T cells (1 × 106/mL) from the
spleen tissue were stimulated for 4.5 hr with phorbol myris-
tate acetate (PMA) at 100 ng/mL and Ionomycin at 1 𝜇g/mL
in the presence of 1.6 𝜇g/mL Monensin (all from Beyotime,
China). Cells were collected, washed, and surface-stained
with FITC-labeled anti-CD4 antibody at 4∘C for 20min in
the dark and resuspended in Fix/Perm solution according
to the manufacturer’s instruction (Invitrogen, USA). They
were then stained intracellularly with PE-labeled anti-IL-17
antibody. After washing, cells were resuspended in fixation
solution and subjected to FACScalibur flow cytometer (BD
FACSCanto II, USA) analysis. Background fluorescence was
assessed by the corresponding isotype control antibodies.
Data were analyzed with WinMDI software.
2.6. Western Blotting. Lung tissue was fragmented and lysed
in RIPA buffer with protease inhibitor mixture (Beyotime,
China). A total protein of 20𝜇g was loaded into each well
of a SDS-PAGE gel for separation by electrophoresis and
then transferred onto nitrocellulosemembrane.The resulting
blots were blocked for 1 h with TBS Tween 20 containing
5% powder skim milk and then probed overnight at 4∘C
with anti-NICD (Abcam, UK). Blots were then washed three
times and probed for 1 h with anti-rabbit HRP-conjugated
antibody. 𝛽-actin mousemAb (Beyotime, China) was used as
the loading control. Immunostained proteins were detected
by ECL.
2.7. Quantitative Real-Time RT-PCR Analysis. RNA was
extracted from lung tissue using Trizol (Invitrogen, USA)
according to the manufacturer’s instruction. cDNA was syn-
thesized by reverse transcription with oligo (dT) from total
RNA. The quantitative real-time RT-PCR was performed
using an ABI Step One Plus System (Applied Biosystems,
USA) with QuantiFast SYBR Green PCR Kit (QIAGEN,
Germany). GAPDH was used as internal control. Primers
used were as follows: GAPDH, 5󸀠-TGGCCTTCCGTG-
TTCCTAC-3󸀠 (forward) and 5󸀠-GAGTTGCTGTTGAAG-
TCGCA-3󸀠 (reverse); Notch1, 5󸀠-TGCCACAATGAGATC-
GGCTC-3󸀠 (forward) and 5󸀠-GAGTTGCTGTTGAAGTCG-
CA-3󸀠 (reverse). Delta-Delta Ct method was used to express
the fold induction of target mRNA after GAPDH normaliza-
tion.
2.8. ELISA. The concentration of cytokines IL-17 in serum
was assessed by standardized sandwich ELISA according to
the manufacturer’s protocol. The IL-17 kit was purchased
from eBioscience, San Diego, USA.
2.9. Statistical Analysis. All data were expressed as Mean ±
SEM.Differences between groupswere analyzed for statistical
significance by one-way analysis of variance using SPSS 13.0
software (SPSS Inc., Chicago, USA). Differences with a P
value < 0.05 were considered statistically significant.
3. Results
3.1. GSI Ameliorates the Severity of Inflammation in OVA-
Induced Asthma. To explore the effect of GSI on OVA-
induced asthma, BABL/C mice were sensitized and chal-
lenged with OVA (or NS for shammice).Thosemice received
GSI, a highly selective inhibitor of 𝛾-secretase or vehicle
(DMSO), during the challenge phase. Mice were sacrificed
within 24 h after the last allergen challenge and lung tissue
was fixed, embedded, and sectioned for HE staining. The
degree of airway inflammation of HE-stained lung tissue was
scored as described in Materials and Methods. As shown in
Figure 2(a), OVA + DMSO group demonstrated significant
infiltration of eosinophils and lymphocytes with marked
thickening of airwaywall and epithelial goblet cellmetaplasia,
as compared with the sham group. GSI treatment reduced
such inflammation and airway wall thickening (Figure 2(b)).
OVA-challenged mice showed an inflammation score of
3.25 ± 0.46 as compared to sham control (0.38 ± 0.52).
GSI treated group showed a score of 1.88 ± 0.64 that is
significantly lower than OVA-DMSO group (Figure 2(b), 𝑃 <
0.01).
3.2. GSI Affects the Expression of Notch Signaling Component.
To investigate the blockage effects of GSI on Notch signaling,
mRNA expression of Notch1, a receptor of Notch signaling,
was examined. As shown in Figure 3(a), OVA-challenged
mice revealed enhanced Notch1 mRNA expression, as com-
pared with the sham group (1.31 ± 0.13 versus 0.84 ± 0.13,
𝑃 < 0.01). On the other hand, GSI treatment led to the reduc-
tion of Notch1 mRNA expression (0.92 ± 0.088 𝑃 < 0.01
comparing to OVA group). Consistent with this observation,
OVA-challenged mice revealed increased NICD generation
as compared to sham group (0.18 ± 0.02 versus 0.09 ± 0.01,
𝑃 < 0.01). GSI treatment decreasedNICD generation (0.06 ±
0.03) comparing to OVA group (Figure 3(b), 𝑃 < 0.01).
Results presented here suggest that GSI can effectively block
Notch signaling.
3.3. GSI Decreases the Frequency of Th17 Cells in the Spleen
of OVA-Induced Asthma Mice. To evaluate the effect of GSI
treatment on Th17 cell expansion, splenic CD4+ T cells were
isolated by magnetic cell sorting. Th17 cells were identified
by IL-17A staining. Sham group expressed a baseline Th17
cell frequency of 0.30 ± 0.16% of total splenic CD4+ T cells.
OVA-induced asthma mice revealed a significant increase of
Th17 cells (2.43 ± 0.69%, 𝑃 < 0.01, comparing to sham
group). GSI treatment reduced Th17 cell frequency to 1.26 ±
0.85% which is statistically significant from OVA group (𝑃 <
0.05, Figure 4). This finding indicates that GSI reduces the
development of Th17 cells.
3.4. GSI Treatment Reduces the Production of IL-17 of Asthma
Mice. Th17 cells are the main source of IL-17. To further
examine the function of such Th17 cells, serum levels of
IL-17 were measured from OVA-induced asthma mice. As
illustrated in Figure 5, sham group expressed a baseline
level of IL-17 in serum at 48.07 ± 5.73 pg/mL. The IL-17
level was significantly elevated in OVA-induced asthma mice
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Figure 2: 𝛾-Secretase inhibitor (GSI) reduced OVA-induced airway inflammation. (a) BALB/C mice were sensitized i.p. with OVA and
challenged with OVA in the presence and absence of GSI. Mice were sacrificed within 24 hr after last challenge. Lung tissues were stained
with haematoxylin and eosin and subjected to light microscope (×200) examination. (b) Semiquantitative pathology scores among sham,
OVA, and OVA + GSI groups. Data expressed as Mean ± SEM.𝑁 = 8mice per group. ∗𝑃 < 0.01 compared with the sham group; #𝑃 < 0.01
compared with the vehicle group.
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Figure 3: GSI decreased Notch1 and NICD. BALB/C mice were sensitized i.p. with OVA and challenged with OVA in the presence and
absence of GSI. (a) The expression of Notch1 mRNA was evaluated by quantitative real-time RT-PCR. GAPDH was used as internal control.
(b) Protein levels of NICD were examined by Western blotting. 𝛽-actin was used as a loading control. (A) Sham group; (B) OVA + DMSO;
(C) OVA + GSI. Data expressed as Mean ± SEM.𝑁 = 8mice per group. ∗𝑃 < 0.01 compared with the sham group. #𝑃 < 0.01 compared with
the vehicle group.
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Figure 4: GSI administration resulted in reducedTh17 cell expansion. BALB/Cmice were sensitized i.p. with OVA and challenged with OVA
in the presence and absence of GSI. Splenic CD4+ T cells were isolated by magnetic cell sorting. Th17 cells were examined by IL-17A staining
and data were analyzed by flow cytometry. Dot plots show as percent of cells positive for CD4 and IL-17A staining. Graphs representative of
one of eight experiments.
(120.09 ± 5.73 pg/mL, 𝑃 < 0.01). GSI administration during
challenge phase significantly reduced the IL-17 level to 81.82±
8.95 pg/mL, 𝑃 < 0.01. These findings confirm the possibility
that GSI downregulates IL-17 expression.
4. Discussion
The Notch signaling pathway is involved in many aspects
of organ formation and cell function [7]. Dysregulation of
Notch signalingmay induce humandisorders such as asthma.
The effect of Notch signaling inhibition on the development
of asthmahas been addressed in several recent studies. Jin and
colleagues reported that inhibition of Notch signal pathway
by GSI alleviated the airway inflammation in OVA-induced
asthma model and it was through the regulation of Th1 and
Th2 responses [11]. Knockdown of the Notch l gene by small
interfering RNA led to overproduction of IL-4 and IFN-𝛾,
which played an important role in the pathogenesis of asthma
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Figure 5: GSI administration reduced production of IL-17. Serum
IL-17 levels were measured from sham, OVA, and OVA plus GSI
groups using standardized sandwich ELISA. Data expressed here are
Mean ± SEM. 𝑁 = 8. ∗𝑃 < 0.01 compared with the sham group.
#
𝑃 < 0.01 compared with the vehicle group.
[13]. However, the exact underlying mechanism is yet to be
fully elucidated.
In the present study, we usedGSI to blockNotch signaling
in a mouse model of asthma and demonstrated that in
vivo administration of GSI effectively attenuated eosinophilic
and lymphocyte infiltration in the airways and decreased
goblet cell metaplasia. Furthermore, Notch inhibition by GSI
reduced the frequency of Th17 cells in spleen and the serum
levels of IL-17. Taken together, these findings demonstrate the
effectiveness of GSI in animal models and strongly suggest
that inhibition of Notch signaling could be an effective
strategy for the treatment of asthma.
T helper 17 (Th17) cells play a critical role in adaptive
immune responses through the production of cytokines,
namely, IL-17A, IL-17F, and IL-22 [14]. Recent studies indicate
thatTh17 cells are active players in acute airway inflammation
of allergic asthma. Marked elevation of IL-17A was detected
in the sputum of severe asthma patients [15]. Excess IL-
17-secreting cells were observed in the lung tissue of such
patients as well [16]. Li et al. [17] suggested that the ratio of
Th17 cells/CD3+ T cells in peripheral blood was significantly
increased in asthma patients compared with nonasthma
individuals. Similar change was found in the present study;
that is, the proportion of Th17 cells in isolated spleen CD4+
T cells was significantly increased in OVA-induced asthma
mice compared to the sham group. McKinley et al. reported
that adaptive transferring of Th17 cells to an asthma mouse
led to neutrophils infiltration and airway hyperresponsive-
ness, which is resistant to corticosteroid therapy [18]. IL-17
mediated airway inflammation may result in severe airway
obstruction. The expression of IL-17A was also noticed
in ozone exacerbated asthma [19]. Consistent with these
findings, our investigation revealed that treatment with GSI
markedly reduced serum IL-17 levels of asthma mice. Of
note, Doe et al. [20] found that IL-17A was elevated in mild
to moderate human asthma compared with healthy control,
while it was not increased in severe asthma.Therefore, further
research is needed to characterize the exact relationship
between IL-17 and the severity of asthma.
Notch can directly regulate retinoic acid-related orphan
receptor 𝛾𝑡, an important transcription factor for Th17
differentiation [21]. The effect of GSI on autoimmune
inflammatory disorders has been addressed in several stud-
ies. 𝛾-Secretase inhibitor treatment can downregulate Th17
response and inhibit vascular inflammation [22]. Inhibition
of Notch signaling by Notch3 antibody attenuates Th17-type
responses, while treatment with Notch ligand Delta-like 1
promotes Th17 response [23]. In vitro knockdown of Notch
and in vivo administration of GSIs result in reduced IL-17
production and substantially impede Th17-mediated disease
progression in mouse model of multiple sclerosis [24]. GSIs
have been actively tested in clinical trials for Alzheimer
disease for their potential in blocking the generation of
A peptide [25]. MRK003, a 𝛾-secretase inhibitor, exhibits
promising in vitro preclinical activity in multiple myeloma
and non-Hodgkin’s lymphoma [26]. After blocking Notch
signaling in our mouse asthma model, we noticed decreased
level of NICD, ameliorated airway inflammation, reduced
serum IL-17 level, and improved clinical signs. Our data
strongly suggest that inhibition of Notch signaling could be
considered as an effective therapy for asthma. Of course,
further preclinical and clinical research is needed to address
such potential.
In conclusion, the current study proves that GSI adminis-
tration inhibits Th17 differentiation, decreases IL-17 produc-
tion, and alleviates airway inflammation in OVA-sensitized
andOVA-challenged BALB/Cmice.These results support the
idea of considering GSI as a novel, effective antiasthma agent.
Abbreviations
Th: T helper
GSI: 𝛾-Secretase inhibitor
AHR: Airway hyperresponsiveness
Dll: Delta-like ligand
NICD: Notch receptor intracellular domain
IACUC: Institutional Animal Care and Use Committee
NS: Normal saline
DMSO: Dimethylsulfoxide
HE: Haematoxylin and eosin
PMA: Phorbol myristate acetate
OVA: Ovalbumin
Th17: IL-17-producing CD4+ Th cells.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Authors’ Contribution
Weixi Zhang and Xueya Zhang contributed equally to this
study.
Mediators of Inflammation 7
Acknowledgments
This work was supported by the National Natural Science
Foundation of China (no. 81100015) and the Zhejiang Provin-
cial Program for the Cultivation of High-level Innovative
Health talents.
References
[1] J. Bousquet, P. K. Jeffery, W. W. Busse, M. Johnson, and A. M.
Vignola, “Asthma: from bronchoconstriction to airways inflam-
mation and remodeling,” American Journal of Respiratory and
Critical Care Medicine, vol. 161, no. 5, pp. 1720–1745, 2000.
[2] A. B. Kay, “The role of T lymphocytes in asthma,” Chemical
Immunology and Allergy, vol. 91, pp. 59–75, 2006.
[3] J. Zhao, C. M. Lloyd, and A. Noble, “Th17 responses in chron-
ic allergic airway inflammation abrogate regulatory T-cell-
mediated tolerance and contribute to airway remodeling,”
Mucosal Immunology, vol. 6, no. 2, pp. 335–346, 2013.
[4] C. Ma, Z. Ma, Q. Fu et al., “Curcumin attenuates allergic airway
inflammation by regulation of CD4+CD25+ regulatory T cells
(Tregs)/Th17 balance in ovalbumin-sensitized mice,” Fitoter-
apia, vol. 87, pp. 57–64, 2013.
[5] C. Herbert, A. M. Shadie, and R. K. Kumar, “Interleukin-17
signalling in a murine model of mild chronic asthma,” Interna-
tional Archives of Allergy and Immunology, vol. 162, no. 3, pp.
253–262, 2013.
[6] Y. Zhao, J. Yang, Y.-D. Gao, and W. Guo, “Th17 immunity in
patients with allergic asthma,” International Archives of Allergy
and Immunology, vol. 151, no. 4, pp. 297–307, 2010.
[7] F. Radtke, N. Fasnacht, and H. R. MacDonald, “Notch signaling
in the immune system,” Immunity, vol. 32, no. 1, pp. 14–27, 2010.
[8] F. Radtke, H. R. MacDonald, and F. Tacchini-Cottier, “Regula-
tion of innate and adaptive immunity byNotch,”Nature Reviews
Immunology, vol. 13, no. 6, pp. 427–437, 2013.
[9] W. Zhang, Y. Nie, L. Chong et al., “PI3K and Notch signal
pathways coordinately regulate the activation and proliferation
of T lymphocytes in asthma,” Life Sciences, vol. 92, no. 17–19, pp.
890–895, 2013.
[10] W. Gu, W. Xu, T. Ding, and X. Guo, “Fringe controls naive
CD4(+)T cells differentiation throughmodulating notch signal-
ing in asthmatic rat models,” PLoS ONE, vol. 7, no. 10, Article ID
e47288, 2012.
[11] H. K. Jin, S. K. Byung, G. U. Tae et al., “𝛾-secretase inhibitor
reduces allergic pulmonary inflammation by modulating Th1
andTh2 responses,”American Journal of Respiratory andCritical
Care Medicine, vol. 179, no. 10, pp. 875–882, 2009.
[12] J. Y. Cho, M. Miller, K. J. Baek et al., “Immunostimulatory DNA
sequences inhibit respiratory syncytial viral load, airway
inflammation, and mucus secretion,” Journal of Allergy and
Clinical Immunology, vol. 108, no. 5, pp. 697–702, 2001.
[13] X. J. Guo, M. Zhou, L. P. Ren et al., “Small interfering RNA-me-
diated knockdown of Notch1 in lung,” Chinese Medical Journal,
vol. 122, no. 21, pp. 2647–2651, 2009.
[14] E. Bettelli, M. Oukka, and V. K. Kuchroo, “Th-17 cells in the cir-
cle of immunity and autoimmunity,”Nature Immunology, vol. 8,
no. 4, pp. 345–350, 2007.
[15] D. M. A. Bullens, E. Truyen, L. Coteur et al., “IL-17 mRNA in
sputum of asthmatic patients: linking T cell driven inflamma-
tion and granulocytic influx?” Respiratory Research, vol. 7, no. 1,
pp. 135–143, 2006.
[16] W.Al-Ramli, D. Pre´fontaine, F. Chouiali et al., “TH17-associated
cytokines (IL-17A and IL-17F) in severe asthma,” Journal of
Allergy and Clinical Immunology, vol. 123, no. 5, pp. 1185–1187,
2009.
[17] K. Li, Z. Wang, Y. Cao et al., “The study of the ratio and distri-
bution ofTh17 cells and Tc17 cells in asthmatic patients and the
mousemodel,”Asian Pacific Journal of Allergy and Immunology,
vol. 31, no. 2, pp. 125–131, 2013.
[18] L. McKinley, J. F. Alcorn, A. Peterson et al., “TH17 cells mediate
steroid-resistant airway inflammation and airway hyperrespon-
siveness in mice,”The Journal of Immunology, vol. 181, no. 6, pp.
4089–4097, 2008.
[19] P. Miossec and J. K. Kolls, “Targeting IL-17 and T
𝐻
17 cells in
chronic inflammation,” Nature Reviews Drug Discovery, vol. 11,
no. 10, pp. 763–776, 2012.
[20] C. Doe, M. Bafadhel, S. Siddiqui et al., “Expression of the T
helper 17-associated cytokines IL-17A and IL-17F in asthma and
COPD,” Chest, vol. 138, no. 5, pp. 1140–1147, 2010.
[21] T. Ito, J. M. Connett, S. L. Kunkel, and A. Matsukawa, “Notch
system in the linkage of innate and adaptive immunity,” Journal
of Leukocyte Biology, vol. 92, no. 1, pp. 59–65, 2012.
[22] K. Piggott, J. Deng, K.Warrington et al., “Blocking the NOTCH
pathway inhibits vascular inflammation in large-vessel vasculi-
tis,” Circulation, vol. 123, no. 3, pp. 309–318, 2011.
[23] Z. Jiao, W. Wang, H. Xu et al., “Engagement of activated Notch
signalling in collagen II-specific T helper type 1 (Th1)- andTh17-
type expansion involving Notch3 and Delta-like1,” Clinical and
Experimental Immunology, vol. 164, no. 1, pp. 66–71, 2011.
[24] S. Keerthivasan, R. Suleiman, R. Lawlor et al., “Notch signaling
regulates mouse and human Th17 differentiation,” The Journal
of Immunology, vol. 187, no. 2, pp. 692–701, 2011.
[25] G. Tong, J.-S. Wang, O. Sverdlov et al., “Multicenter, ran-
domized, double-blind, placebo-controlled, single-ascending
dose study of the oral 𝛾-secretase inhibitor BMS-708163 (Ava-
gacestat): tolerability profile, pharmacokinetic parameters, and
pharmacodynamic markers,” Clinical Therapeutics, vol. 34, no.
3, pp. 654–667, 2012.
[26] V. Ramakrishnan, S. Ansell, J. Haug et al., “MRK003, a 𝛾-secre-
tase inhibitor exhibits promising in vitro pre-clinical activity in
multiple myeloma and non-Hodgkin’s lymphoma,” Leukemia,
vol. 26, no. 2, pp. 340–348, 2012.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
